InSilicoTrials is an emerging startup founded by a team of life science, cybersecurity and digital innovation experts, which aims to revolutionize Healthcare through an innovative digital simulation platform. We specialize in leveraging AI and simulations to enhance drug development. Using in silico techniques, we analyze data to predict safety and efficacy of potential compounds, aiding Pharma, biotech companies, and researchers in efficient, cost-effective R&D advancement by minimizing extensive clinical trials. InSilicoTrials’ cloud-based platform offers advanced tools for in silico trials analyses, facilitating the integration of AI and simulation technology into drug development workflows.

INTA, a spinoff of the Scuola Normale Superiore (University of Pisa) and National Research Council of Italy (CNR-NANO), specializes in developing portable, multiplexed, rapid, and cost-effective biosensing systems, primarily focusing on diagnosing mild traumatic brain injuries (TBI). Founded on deep-tech innovation from research in nanoelectronics and biotechnology, INTA’s NanoAnalyzer platform offers a unique solution by bridging the gap between high-cost, lab-based tests and low-cost, low-performance rapid tests. With more than €2.5 million raised and a solid strategy to expand its applications for TBI and other pathologies or areas such as environmental monitoring and food safety, INTA is poised for significant growth in the biosensor market.